Achieve Life Sciences
Closed portfolio snapshot
According to ClinicalTrials.gov-derived indexes, Achieve Life Sciences sits in the top decile of US sponsors by registered trial count (#842 of 15,742 sponsors by registered trial count).
Achieve Life Sciences: 17 sponsored US clinical trials, none currently recruiting.
Achieve Life Sciences sponsors 17 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 15 completed. 8 of these trials are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Urinary Tract Neoplasms, with 1 trials.
Top-decile sponsor footprint
Achieve Life Sciences ranks in the top decile of sponsors by registered trial count (#842 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
15 of 17 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.2%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
17 total, page 1 of 1
Safety Study of Cytisinicline in Adult Combustible and/or E-cigarette Smokers
NCT06435221
A Study of Cytisinicline for Vaping Cessation in Adult Smokers
NCT05431387
A Second Study of Cytisinicline for Smoking Cessation in Adult Smokers
NCT05206370
A Study of Cytisinicline for Smoking Cessation in Adult Smokers
NCT04576949
Trial of Cytisine in Adult Smokers
NCT03709823
Thorough QT/QTc (Corrected QT Interval) Study to Evaluate the Effect of Custirsen on Cardiac Repolarization
NCT01874561
A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer
NCT01630733
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
NCT01578655
A Clinical Study in Cancer Patients to Investigate the Potential Impact of Custirsen, on the Blood Levels of the Chemotherapeutic Drug, Paclitaxel, When Given Together as Part of a Treatment Regimen
NCT01497470
A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer
NCT01454089
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
NCT01188187
A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
NCT01083615
Safety Study of an Antisense Product in Prostate, Ovarian, NSCL, Breast or Bladder Cancer
NCT00487786
Phase 1 Dose Escalation Study of SN2310 Injectable Emulsion in Patients With Advanced Solid Tumors
NCT00385177
Comparison of Safety and Efficacy of TOCOSOL(R) Paclitaxel Versus Taxol(R) for Treatment of Metastatic Breast Cancer
NCT00251095
A Study of OGX-011/Gemcitabine/Platinum-Based Regimen in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)
NCT00138658
TOCOSOL(TM) Paclitaxel in Metastatic or Locally Advanced Unresectable Transitional Cell Carcinoma of the Urothelium
NCT00077688
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 4 |
| Phase 3 | 8 |
Therapeutic Areas
How the Achieve Life Sciences archive is shaped
17 indexed studies, none listed as recruiting (0% open); 15 completed (88%).
Phase mix: 8 late (III/IV) vs 9 early (I/II) (balanced across stages).
Top condition: Urinary Tract Neoplasms (1 trial), 3 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Achieve Life Sciences: archived-pipeline peers nationwide
Peers matched on 17 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Achieve Life Sciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 17 archived trials
- BioDelivery Sciences International · 17 trials · 6% recruiting
- Chugai Pharmaceutical · 17 trials · 24% recruiting
- ConvaTec · 17 trials · 18% recruiting
- Durham VA Medical Center · 17 trials · 6% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Achieve Life Sciences page
17 registered trials is a research-attention snapshot, not an endorsement of Achieve Life Sciences or any single study.
- None of Achieve Life Sciences's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Urinary Tract Neoplasms is the condition Achieve Life Sciences studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Urinary Tract Neoplasms trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Achieve Life Sciences pipeline card: 17 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.